Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Financing Activities (2018 - 2025)

UroGen Pharma's Cash from Financing Activities history spans 8 years, with the latest figure at $31.3 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 44007.04% year-over-year to $31.3 million; the TTM value through Dec 2025 reached $39.9 million, down 79.49%, while the annual FY2025 figure was $39.9 million, 79.49% down from the prior year.
  • Cash from Financing Activities reached $31.3 million in Q4 2025 per URGN's latest filing, up from $8.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $116.1 million in Q3 2023 to a low of -$168000.0 in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $26.0 million, with a median of $886000.0 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: plummeted 375.41% in 2021, then soared 1768450.0% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$32000.0 in 2021, then soared by 79375.0% to $25.4 million in 2022, then crashed by 99.84% to $40000.0 in 2023, then skyrocketed by 77.5% to $71000.0 in 2024, then skyrocketed by 44007.04% to $31.3 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Cash from Financing Activities are $31.3 million (Q4 2025), $8.3 million (Q3 2025), and $296000.0 (Q2 2025).